Miracle-dz/UniFAR-FTUs huggingface dataset:
Improved and Efficient Process for the Production of Highly Pure Iloperidone: A Psychotropic Agent

The present work describes an improved and highly efficient process for the synthesis of iloperidone (1), an antipsychotic agent, which is free from potential impurities. The synthesis comprises N-alkylation of 1-(4-(3-chloropropoxy)-3-methoxyphenyl)ethanone (4) with 6-fluoro-3-piperidin-4-yl-1,2-benzisoxazole hydrochloride (5) in a mixture of water and heptane as solvent and sodium hydroxide as a base in the presence of tetrabutylammonium bromide as a phase transfer catalyst to yield iloperidone (1) with a yield of around 95% and a purity of 99.80% by HPLC. The present work also describes the optimization details performed to achieve the process attributes responsible for high yield and purity.
A fuzzy integrated congestion-aware routing algorithm for network on chip

Network on chip (NoC) is an infrastructure providing a communication platform to multiprocessor chips. Furthermore, the wormhole-switching method, which shares resources, was used to increase its efficiency; however, this can lead to congestion. Moreover, dealing with this congestion consumes more energy and correspondingly leads to increase in power consumption. Furthermore, consuming more power results in more heat and increases thermal fluctuations that lessen the life span of the infrastructures and, more importantly, the network’s performance. Given these complications, providing a method that controls congestion is a significant design challenge. In this paper, a fuzzy logic congestion control routing algorithm is presented to enhance the NoC’s performance when facing congestion. To avoid congestion, the proposed algorithm employs the occupied input buffer and the total occupied buffers of the neighboring nodes along with the maximum possible path diversity with minimal path length from instant neighbors to the destination as the selection parameters. To enhance the path selection function, the uncertainty of the fuzzy logic algorithm is used. As a result, the average delay, power consumption, and maximum delay are reduced by 14.88%, 7.98%, and 19.39%, respectively. Additionally, the proposed method enhances the throughput and the total number of packets received by 14.9% and 11.59%, respectively. To show the significance, the proposed algorithm is examined using transpose traffic patterns, and the average delay is improved by 15.3%. The average delay is reduced by 3.8% in TMPEG-4 (treble MPEG-4), 36.6% in QPIP (quadruplicate PIP), and 20.9% in TVOPD (treble VOPD).
Correlation between platelet count and outcome of chronic HCV patients treated with direct-acting antivirals

Background: Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection. Thedirect acting anti-virus (DAAs) are available, with a reported 95% sustained virological responseafter treatment for 12 weeks (12w-SVR). Objectives: The current study aimed to assess the correlation between platelet count and theDAAs therapy outcome in chronic HCV (CHC) patients.Patients and methods: three hundred CHC patients, Child–Pugh grade A, both naive andtreatment experienced patients were enrolled in this study, from outpatient Clinic, Department ofGastroenterology, Hepatology and Tropical medicine, Qena university hospital, Qena, Egypt,treated with DAAs for 12 weeks, either dual or triple therapy, according to criteria recommendedby the national committee for chronic viral hepatitis (NCCVH). Patients categorized into threegroups: (1) Group I (non-thrombocytopenic group): included 100 CHC patients with platelet count≥ 150 (109/L); (2) Group II (mild thrombocytopenic group): included 100 CHC patients withplatelet count 100-149 (109/L); (3) Group III (moderate thrombocytopenia): included 100 CHCpatients with platelet count 50–99 (109/L). Results: The Overall CHC patient's mean age were (48.2 ± 11), 226 (75.33%) were males and 74(24.67%) were females. 97.6% (293/300)of CHC patients attainedSVR; 97 % in (Group I), and 98% in both (Group II), and (Group III), after 12 weeks DAAs therapy with no significant differencebetween groups.Conclusion: both DAAs treatment modalities were efficient in the eradication of HCV; however,thrombocytopenia in CHC patients does not affect the DAAs therapy outcome.